Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $24.3 million.

  • Mirum Pharmaceuticals' Change in Accured Expenses rose 9091.91% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 2873.04%. This contributed to the annual value of $40.3 million for FY2024, which is 3097.67% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Change in Accured Expenses stood at $24.3 million, which was up 9091.91% from $10.6 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $24.3 million during Q3 2025, with a 5-year trough of -$8.1 million in Q1 2022.
  • For the 5-year period, Mirum Pharmaceuticals' Change in Accured Expenses averaged around $7.8 million, with its median value being $9.2 million (2023).
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Change in Accured Expenses crashed by 34491.69% in 2021, and later skyrocketed by 25066000.0% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $9.0 million in 2021, then plummeted by 100.06% to -$5000.0 in 2022, then surged by 250660.0% to $12.5 million in 2023, then dropped by 25.45% to $9.3 million in 2024, then soared by 160.69% to $24.3 million in 2025.
  • Its Change in Accured Expenses was $24.3 million in Q3 2025, compared to $10.6 million in Q2 2025 and $11.7 million in Q1 2025.